Reliable anti-cancer drug sensitivity prediction and prioritization

被引:1
|
作者
Lenhof, Kerstin [1 ]
Eckhart, Lea [1 ]
Rolli, Lisa-Marie [1 ]
Volkamer, Andrea [2 ]
Lenhof, Hans-Peter [1 ]
机构
[1] Saarland Univ, Chair Bioinformat, Ctr Bioinformat, Saarland Informat Campus E2 1, D-66123 Saarbrucken, Saarland, Germany
[2] Saarland Univ, Chair Data Driven Drug Design, Ctr Bioinformat, Saarland Informat Campus E2 1, D-66123 Saarbrucken, Saarland, Germany
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
Reliability; Conformal prediction; Simultaneous regression and classification; Drug sensitivity prediction; Drug prioritization; Cancer; CONFORMAL PREDICTION; PRECISION;
D O I
10.1038/s41598-024-62956-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The application of machine learning (ML) to solve real-world problems does not only bear great potential but also high risk. One fundamental challenge in risk mitigation is to ensure the reliability of the ML predictions, i.e., the model error should be minimized, and the prediction uncertainty should be estimated. Especially for medical applications, the importance of reliable predictions can not be understated. Here, we address this challenge for anti-cancer drug sensitivity prediction and prioritization. To this end, we present a novel drug sensitivity prediction and prioritization approach guaranteeing user-specified certainty levels. The developed conformal prediction approach is applicable to classification, regression, and simultaneous regression and classification. Additionally, we propose a novel drug sensitivity measure that is based on clinically relevant drug concentrations and enables a straightforward prioritization of drugs for a given cancer sample.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
    Shoyo Shibata
    Maiko Matsushita
    Yoshimasa Saito
    Takeshi Suzuki
    Therapeutic Innovation & Regulatory Science, 2018, 52 : 442 - 448
  • [32] Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan
    Shibata, Shoyo
    Matsushita, Maiko
    Saito, Yoshimasa
    Suzuki, Takeshi
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (04) : 442 - 448
  • [33] METFORMIN - FROM ANTI-DIABETIC DRUG TO ANTI-CANCER DRUG
    Markowicz-Piasecka, Magdalena
    Huttunen, Kristiina M.
    Mikiciuk-Olasik, Elzbieta
    Mateusiak, Lukasz
    Sikora, Joanna
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (01): : 3 - 18
  • [34] The unfolded protein response pathway plays a key role in anti-cancer drug sensitivity
    Nitiss, J
    Gray, M
    Nitiss, K
    Hendershot, L
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S91 - S91
  • [35] PEG based anti-cancer drug conjugated prodrug micelles for the delivery of anti-cancer agents
    Senevirathne, Suchithra A.
    Washington, Katherine E.
    Biewer, Michael C.
    Stefan, Mihaela C.
    JOURNAL OF MATERIALS CHEMISTRY B, 2016, 4 (03) : 360 - 370
  • [36] Drug signaling network-based prediction of therapeutic response to anti-cancer agents
    Kim, Youngchul
    Theodorescu, Dan
    Lee, Jae K.
    CANCER RESEARCH, 2010, 70
  • [37] A Hybrid Interpolation Weighted Collaborative Filtering Method for Anti-cancer Drug Response Prediction
    Zhang, Lin
    Chen, Xing
    Guan, Na-Na
    Liu, Hui
    Li, Jian-Qiang
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [38] ψ-Bufarenogin, a lead compound of anti-cancer drug
    Ding, Jin
    Wang, Hongyang
    CELL CYCLE, 2015, 14 (17) : 2719 - 2720
  • [39] NEW APPROACH TO ANTI-CANCER DRUG DEVELOPMENT
    LANDES, RC
    BRITISH JOURNAL OF CANCER, 1975, 31 (02) : 254 - 254
  • [40] PET in anti-cancer drug development and therapy
    Kumar, Rakesh
    Lal, Neena
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (03) : 259 - 263